Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes

British Journal of Clinical Pharmacology

Volumn 45, Issue 2, 1998, Pages 107-114

  Eagling, Victoria A ^a   Tjia, John F ^a   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cytochrome P450; Cytochrome P450 inhibition; Differential selectivity

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; KETOCONAZOLE; PHENACETIN; SULFAPHENAZOLE; TESTOSTERONE; TOLBUTAMIDE;

ANIMAL TISSUE; ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CHLORZOXAZONE; CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; ENZYME INHIBITORS; HUMANS; KETOCONAZOLE; KINETICS; MALE; MICROSOMES, LIVER; PHENACETIN; RATS; RATS, WISTAR; SUBSTRATE SPECIFICITY; SULFAPHENAZOLE; TESTOSTERONE; THEOPHYLLINE; TOLBUTAMIDE;

EID: 0031962621     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00679.x     Document Type: Article

References (37)

1. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993; 4: 292-294.
2. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BR. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 1993; 25: 453-483.
3. Paine AJ. Heterogeneity of cytochrome P450 and its toxicological significance. Human Exp Toxicol 1995; 14: 1-7.
4. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich, FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogenes and toxic chemicals. Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
5. Nedelcheva D, Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 1994; 24: 1151-1175.
6. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminski LS. Purification and characterization of liver microsomal cytochromes P450: Electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital and alpha-naphthoflavone. Biochem 1982; 21: 6019-6031.
7. Veronese ME, McManus ME, Laupattarakasem P, Miners JO, Birkett DJ. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450. Drug Metab Dispos 1990; 18: 356-361.
8. Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 1993; 6: 649-656.
9. Sesardic D, Boobis AR, Murray BP, et al. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. Br J Clin Pharmacol 1990; 29: 651-663.
10. Halpert JR, Guengerich FP, Bend JR, Correia MA. Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 1994; 125: 163-175.
11. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991; 4: 168-179.
12. Sheets JJ, Mason JI. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. Drug Metab Dispos 1984; 12: 603-606.
13. Meredith CG, Maldonado AL, Speeg KV. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Dispos 1985; 13: 156-162.
14. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P-450 from human hepatocytes in primary culture. FASEB 1992; 6: 752-758.
15. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochromes 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.
16. Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytion hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252: 442-447.
17. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990; 3: 566-573.
18. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism. Identification of the major microsomal steroid 6β hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 1998; 290: 160-166.
19. Purba HS, Maggs JL, Orme M.L'E, Back DJ, Park BK. The metabolism of 17α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmacol 1987; 23: 447-453.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein determination with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
21. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharamacol 1998; 26: 23-29.
22. Carriere V, Goasduff T, Ratanasavanh D, Morel F. Both cytochromes P4502E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 1993; 6: 852-857.
23. Gorski JC, Jones DR, Wrighton SA, Hall SD. Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica 1997; 27: 243-256.
24. Jayyosi Z, Knoble D, Mue M, Eric J, Thomas PE, Kelley M. Cytochrome P450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. J Pharmacol Exp Ther 1995; 273: 1156-1161.
25. Boobis AR, Sesardic D, Murray BP, et al. Species variation in the response of the cytochrome P450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 1990; 20: 1139-1161.
26. Sesardic D, Edwards RJ, Davies DS, et al. High affinity O-deethylase is catalysed specifically by cytochrome P450d (P450IA2) in the liver of the rat. Biochem Pharmacol 1990; 39: 489-498.
27. Soucek P, Gut I. Review. Cytochromes P-450 in rats: Structures, functions, properties and relevant human forms. Xenobiotica 1992; 22: 83-103.
28. Lewis DFV, Lake BG. Molecular modelling of CYP1A subfamily members based on sequence alignment with CYP102: rationalisation of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica 1996; 26: 723-753.
29. Baldwin JJ, Bloomer JC, Smith, GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
30. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site directed mutagenesis of human liver cytochrome P450 isozymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
31. Jones BC, Hawksworth G, Newlands A, Morsman J, Tute MS, Smith DA. Putative active site template model for Cytochrome P4502C9 (tolbutamide hydroxylase). Drug Metab Dispos 1996; 24: 260-266.
32. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
33. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch Biochem Biophys 1994; 311: 437-442.
34. Halpert JR. Structural basis of selective cytochrome P450 inhibition. Ann Rev Pharmacol Toxicol 1995; 35: 29-53.
35. Imaoka S, Terano Y, Funae Y. Constitutive 6β-hydroxylase in rat liver. J Biochem 1988; 104: 481-487.
36. 19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes. J Biol Chem 1983; 14: 8839-8847.
37. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987; 255: 27-41.